DK1105132T3 - Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø - Google Patents

Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø

Info

Publication number
DK1105132T3
DK1105132T3 DK99936000T DK99936000T DK1105132T3 DK 1105132 T3 DK1105132 T3 DK 1105132T3 DK 99936000 T DK99936000 T DK 99936000T DK 99936000 T DK99936000 T DK 99936000T DK 1105132 T3 DK1105132 T3 DK 1105132T3
Authority
DK
Denmark
Prior art keywords
dimethoxyphenyl
fluorophenyl
treatment
ethyl
sleep apnea
Prior art date
Application number
DK99936000T
Other languages
Danish (da)
English (en)
Inventor
Cesare Mondadori
Stephen M Sorensen
Janice M Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1105132T3 publication Critical patent/DK1105132T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99936000T 1998-08-28 1999-07-29 Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø DK1105132T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313598A 1998-08-28 1998-08-28
PCT/US1999/017331 WO2000012090A1 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (1)

Publication Number Publication Date
DK1105132T3 true DK1105132T3 (da) 2003-11-24

Family

ID=22502745

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99936000T DK1105132T3 (da) 1998-08-28 1999-07-29 Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø

Country Status (32)

Country Link
EP (2) EP1105132B1 (ko)
JP (1) JP2002523460A (ko)
KR (3) KR100735513B1 (ko)
CN (1) CN1127954C (ko)
AT (1) ATE249830T1 (ko)
AU (1) AU764604B2 (ko)
BG (2) BG65416B1 (ko)
BR (1) BR9913242A (ko)
CA (2) CA2629396A1 (ko)
CZ (1) CZ300781B6 (ko)
DE (2) DE69911436T2 (ko)
DK (1) DK1105132T3 (ko)
EA (1) EA003791B1 (ko)
EE (1) EE04951B1 (ko)
ES (1) ES2204146T3 (ko)
HK (1) HK1040907B (ko)
HR (2) HRP20010140A2 (ko)
HU (1) HUP0202145A3 (ko)
ID (1) ID29601A (ko)
IL (2) IL141603A0 (ko)
ME (1) MEP20308A (ko)
MX (1) MXPA01002026A (ko)
NO (2) NO20010984L (ko)
NZ (1) NZ510083A (ko)
PL (1) PL195022B1 (ko)
PT (1) PT1105132E (ko)
SK (1) SK284858B6 (ko)
TR (1) TR200100670T2 (ko)
TW (1) TWI233802B (ko)
UA (1) UA74773C2 (ko)
WO (1) WO2000012090A1 (ko)
ZA (1) ZA200101466B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
ES2281666T3 (es) 2002-07-19 2007-10-01 Biovitrum Ab Novedosos derivados de piperazinil-pirazinona para el tratamiento de los desordenes relacionados con el receptor 5-ht2a.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
JPH05134149A (ja) * 1991-11-08 1993-05-28 Nippondenso Co Ltd 光半導体モジユール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US9702597B1 (en) 2016-02-18 2017-07-11 King Fahd University Of Petroleum And Minerals System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

Also Published As

Publication number Publication date
HUP0202145A3 (en) 2003-02-28
ZA200101466B (en) 2002-05-21
IL141603A (en) 2006-08-20
EP1362589A1 (en) 2003-11-19
DE69911436T2 (de) 2004-07-01
NO20010984D0 (no) 2001-02-27
CZ2001726A3 (en) 2001-06-13
HRP20010140A2 (en) 2002-02-28
KR100682799B1 (ko) 2007-02-15
HK1040907B (zh) 2004-04-02
KR20010073026A (ko) 2001-07-31
DE69941134D1 (de) 2009-08-27
CA2341891C (en) 2009-05-12
PT1105132E (pt) 2004-02-27
HK1040907A1 (en) 2002-06-28
NO20091111L (no) 2001-04-25
EE200100122A (et) 2002-06-17
NZ510083A (en) 2003-08-29
NO20010984L (no) 2001-04-25
AU764604B2 (en) 2003-08-21
CN1315861A (zh) 2001-10-03
EP1362589B1 (en) 2009-07-15
BG65416B1 (bg) 2008-07-31
SK284858B6 (sk) 2006-01-05
KR20060023197A (ko) 2006-03-13
ATE249830T1 (de) 2003-10-15
CZ300781B6 (cs) 2009-08-12
EA003791B1 (ru) 2003-10-30
ID29601A (id) 2001-09-06
BG109953A (en) 2007-12-28
AU5135999A (en) 2000-03-21
TR200100670T2 (tr) 2001-06-21
PL195022B1 (pl) 2007-08-31
MEP20308A (en) 2010-06-10
EE04951B1 (et) 2008-02-15
HUP0202145A2 (hu) 2003-01-28
DE69911436D1 (de) 2003-10-23
IL141603A0 (en) 2002-03-10
CA2629396A1 (en) 2000-03-09
EA200100201A1 (ru) 2001-08-27
BG105289A (en) 2001-11-30
CA2341891A1 (en) 2000-03-09
KR100764532B1 (ko) 2007-10-09
WO2000012090A1 (en) 2000-03-09
ES2204146T3 (es) 2004-04-16
MXPA01002026A (es) 2003-03-27
EP1105132B1 (en) 2003-09-17
EP1105132A1 (en) 2001-06-13
SK2692001A3 (en) 2001-07-10
JP2002523460A (ja) 2002-07-30
HRP20080389A2 (en) 2008-11-30
TWI233802B (en) 2005-06-11
UA74773C2 (en) 2006-02-15
PL346342A1 (en) 2002-02-11
BR9913242A (pt) 2001-05-15
CN1127954C (zh) 2003-11-19
KR100735513B1 (ko) 2007-07-06
KR20060057029A (ko) 2006-05-25

Similar Documents

Publication Publication Date Title
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
DK0998287T3 (da) Anvendelse af levobupivacain
DK0888114T3 (da) Anvendelse af (+)-alfa-(2,3-dimethoxyphenyl)-1-[2-(4-flourphenyl)-ethyl]-4-piperidinmethanol til behandling af depressive lidelser og bipolare lidelser
IL152908A0 (en) USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
DE69836783D1 (de) Methode zur Behandlung des Tourette-Syndroms
DK1105132T3 (da) Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø
MXPA04000775A (es) Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
MY111623A (en) Neuroprotective compounds
HK1054198A1 (en) Novel use of (R)-(-)-2-Ä5-(4-fluorophenyl)-3-pyridylmethylaminomethylÜ-chromane and its physiologically acceptable salts.
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DK1007522T3 (da) 2-4-[4-(4,5-dichlor-2-methylimidazol-1-yl)butyl]-1-piperazin-1-yl-5-fluorpyrimidin, fremstilling deraf og terapeutisk anvendelse deraf